Alzheimer’s drugs fail, but lessons are learned
After the failure of two novel drugs using antibodies to fight the buildup of brain plaque in Alzheimer’s patients, scientists said on Wednesday they have learned lessons for the future.
The biologic drugs solanezumab, by pharmaceutical giant Eli Lilly, and bapineuzumab, by Johnson and Johnson, made it to phase III trials and were taken by thousands of patients, according to a full report on the research published in the New England Journal of Medicine.
